

P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021

<https://marketpublishers.com/r/PED00B180F36EN.html>

Date: November 2021

Pages: 70

Price: US\$ 3,500.00 (Single User License)

ID: PED00B180F36EN

Abstracts

P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021

SUMMARY

P2X Purinoceptor 3 (P2RX3) - P2X purinoceptor 3 is a protein encoded by the P2RX3 gene. It belongs to the family of purinoceptors. This receptor functions as a ligand-gated ion channel and transduce ATP-evoked nociceptor activation. This receptor is important for peripheral pain responses, and also participates in pathways controlling urinary bladder volume reflexes.

P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 1, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Respiratory, Dermatology, Genito Urinary System And Sex Hormones, Ophthalmology and Women's Health which include indications Chronic Cough, Pain, Cough, Neuropathic Pain (Neuralgia), Inflammatory Pain, Pruritus, Visceral Pain, Alzheimer's Disease, Diabetic Neuropathic Pain, Endometriosis, Insomnia, Low Back Pain, Obstructive Sleep Apnea, Ocular Hypertension, Open-Angle Glaucoma and Overactive Bladder.

The latest report P2X Purinoceptor 3 - Drugs In Development, 2021, outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action

(MoA), route of administration (RoA) and molecule type. It also reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 3 (P2RX3)

The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlists all their major and minor projects

The report assesses P2X Purinoceptor 3 (P2RX3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

P2X Purinoceptor 3 (P2RX3) - Overview

P2X Purinoceptor 3 (P2RX3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development

Asana BioSciences LLC

Bayer AG

Beijing Tide Pharmaceutical Co Ltd

BELLUS Health Inc

Future Analgesics

Integral Molecular Inc

Merck & Co Inc

Neurim Pharmaceuticals Ltd

Ossianix Inc

Shionogi & Co Ltd

Sino Biopharmaceutical Ltd

P2X Purinoceptor 3 (P2RX3) - Drug Profiles

ASN-009 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-5937 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eliapixant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FA-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gefapixant citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSX-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piromelatine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sivopixant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize P2X3 for Inflammatory Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize P2X3 Receptor for Chronic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize P2X3 for Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TCR-1672 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TDI-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P2X Purinoceptor 3 (P2RX3) - Dormant Products

P2X Purinoceptor 3 (P2RX3) - Discontinued Products

P2X Purinoceptor 3 (P2RX3) - Product Development Milestones

Featured News & Press Releases

Nov 01, 2021: BELLUS Health convenes virtual analyst event to discuss the chronic cough landscape and its selective P2X3 antagonist BLU-5937

Oct 08, 2021: Sino Biopharmaceutical announces IND application of innovative medicine "TCR1672" filed with and accepted by FDA

Sep 23, 2021: BELLUS Health announces completion of patient enrollment in SOOTHE phase 2b trial for refractory chronic cough and BLUEPRINT phase 2a trial for chronic pruritus associated with atopic dermatitis

Sep 13, 2021: BELLUS Health announces positive interim analysis from the phase 2b SOOTHE trial of BLU-5937 in refractory chronic cough

Sep 06, 2021: Bayer's Eliapixant significantly decreased cough frequency in Phase IIb trial in patients with refractory chronic cough

Aug 23, 2021: BELLUS Health to report additional RELIEF data in an oral presentation at the European Respiratory Society International Congress 2021

Aug 03, 2021: Evotec SE: Positive phase IIb data for investigational P2X3 antagonist in patients with refractory chronic cough

May 10, 2021: BELLUS Health to present at the American Thoracic Society 2021 International Conference

Mar 03, 2021: MSD files refractory cough medicine in Japan

Mar 01, 2021: U.S. FDA accepts Merck's gefapixant New Drug Application for review

Jan 14, 2021: BELLUS Health to present at the Eleventh International Virtual Cough Symposium

Dec 14, 2020: BELLUS Health announces first patient dosed in its phase 2 BLUEPRINT trial of BLU-5937 for the treatment of chronic pruritus associated with atopic dermatitis

Dec 08, 2020: BELLUS Health announces first patient dosed in its phase 2b SOOTHE trial of BLU-5937 for the treatment of refractory chronic cough

Sep 09, 2020: Merck's gefapixant decreases chronic cough frequency in Phase III trials

Sep 08, 2020: BELLUS Health announces design for its phase 2b Ttrial with BLU-5937 in refractory Chronic Cough

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Asana BioSciences LLC, 2021
Pipeline by Bayer AG, 2021
Pipeline by Beijing Tide Pharmaceutical Co Ltd, 2021
Pipeline by BELLUS Health Inc, 2021
Pipeline by Future Analgesics, 2021
Pipeline by Integral Molecular Inc, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by Neurim Pharmaceuticals Ltd, 2021
Pipeline by Ossianix Inc, 2021
Pipeline by Shionogi & Co Ltd, 2021
Pipeline by Sino Biopharmaceutical Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/PED00B180F36EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PED00B180F36EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970